In this week’s View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to baseline kidney function. Finally, Dr. Eagle examines how low operator volume is associated with worse transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) outcomes.

X Links:

• Kim Eagle, MD, MACC keaglemd
Subscribe to the Eagle's Eye View Podcast